

URGENT
PRESS RELEASE



Wockhardt Limited
Wockhardt Towers
Bandra Kurla Complex
Bandra (East), Mumbai 400 051, India
Tel.: +91 22 2653 4444 +91 22
2653 4444
Fax: +91 22 2653 4242
Website: www.wockhardt.com

Wockhardt's Q1 (Apr-Jun) FY 2011

Consolidated Sales was Rs. 922 crore
Operating Profit (EBIDTA) was Rs. 180 crore
Wockhardt's US, UK & India Branded Business posts double-digit growth

Mumbai, 13 Aug, 2010

Pharmaceutical and Biotechnology major Wockhardt Limited today announced its results for the first quarter ending June 30 of the financial year 2011. Consolidated sales revenues stood at ` 922 crore and operating profit (EBIDTA) was ` 180 crore. Due to exceptional items, the net loss was ` 116 crore.

USA Business:

Wockhardt continues to stabilise and gain critical mass with technologically breakthrough product launches in the US. Wockhardt USA grew by 17% and Morton Grove Pharmaceuticals has shown a 13% growth in Apr-Jun 2010 over the corresponding period of 2009. Wockhardt USA received 2 ANDA approvals in the said quarter and now offers a product basket of 88 products in the US market.

Europe Business:

Wockhardt UK has shown a robust growth of 35% compared to the industry growth of only 5.5% in Apr-Jun 2010. Growth drivers were Hospital products that grew by 16% and exports by 24%. During the said period, it also received 3 product approvals from the UK MHRA and successfully executed a multi-million pound DOH special tender. Pinewood Healthcare's domestic business has shown encouraging results with a 6% growth compared to the industry growth rate of 3% in Apr-Jun 2010. Three new products were launched in the quarter and exports were up by 12%. Negma Laboratories' beta blocking brand, Nebilox grew by 19% during the same period.

India Business:

Wockhardt's India branded business grew by 16% in Apr-Jun 2010 over the corresponding period of 2009 thus improving its rank to 14 with a market share of 2% as per AIOCD-AWACS, June 2010. The Nutrition business grew by 28%, the generics business grew by 26% and exports grew by 63%. Wockhardt's Power Brands have shown consistent growth of 22%.

About Wockhardt

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 14 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, UK MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dosage forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including the US, UK, Ireland and France with a multi-ethnic workforce from 14 different nationalities.

For more information, visit www.wockhardt.com
Corporate Relations Department

For press enquiries about Wockhardt, please contact

➤ Daryl Suchitha
Associate Vice President - Corporate Relations
Wockhardt Limited
Wockhardt Towers, Bandra-Kurla Complex,
Bandra East, Mumbai 400 051, India.

Tel. : + 91 - 22 - 2653 4444 + 91 - 22 - 2653 4444
 Extension: 6303
Direct
Tel.: + 91 - 22 - 2659 6303 + 91 - 22 - 2659 6303
Fax: + 91 - 22 - 2653 4242
Email: daryls@wockhardt.com

Disclaimer:

The company would like to caution that any forward-looking statements or projections made by the company, including those made in the press release announcements, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.